Effectiveness of an Individualized Symptom Education Program (ISEP)
NCT ID: NCT00275353
Last Updated: 2006-05-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
144 participants
INTERVENTIONAL
2003-07-31
2006-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
It is expected that women who participate in the ISEP program will be better able to manage their symptoms and exprience less distress than women who receive usual care.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This study will compare two types of education: 1) the symptom education program currently in place (usual care), and 2) an individualized symptom education program (ISEP). This study is being conducted because we do not know if one type of education in patients who receive radiation for gynecological cancers is better than the other. Both types of education are are described below.
Usual care: Usual symptom education during radiation treatment consists of receiving verbal and written education from a radiation oncologist, nurse and radiation therapist, and other members of the interdisciplinary team. The radiation therapist will see the patient everyday during her radiation treatment and her doctor and nurse will see her on a weekly basis. The patient will also see other members of the team, such as a dietitian and social worker as required.
Individualized symptom education: Individualized symptom education will include usual symptom education and also an education program that focuses on symptom management. The patient will meet with an advanced practice nurse on a weekly basis for six sessions of about 30 minutes each. The advanced practice nurse will ask about the symptoms the paient is experiencing and those that are most bothersome to her. She will be given information about specific strategies to manage those symptoms, including written education materials. These strategies will be based on published best practice guidelines.
Data on symptom experience will be collected at 3 points: at baseline, after completion of the education program (end of external beam treatment), and at 3 months following completion of the education program (3 months following completion of external radiation treatment).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Individualized Symptom Education
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Beginning first time radical radiation therapy to the pelvis of at least 4000cGy (with or without brachytherapy after external beam treatment and with or without concurrent chemotherapy)
* At least 18 years of age and over
* Able to speak and understand English
Exclusion Criteria
* Receiving split course radiation treatment
* Ovarian cancer
18 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Canadian Cancer Trials Group
NETWORK
University of Toronto
OTHER
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Karima Velji, RN, MSc, AOCN, PhD(C)
Role: PRINCIPAL_INVESTIGATOR
University of Toronto
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Princess Margaret Hospital; Toronto Sunnybrook Reginal Cancer Centre
Toronto, Ontario, Canada
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
014144
Identifier Type: -
Identifier Source: secondary_id
14927
Identifier Type: -
Identifier Source: secondary_id
12048
Identifier Type: -
Identifier Source: secondary_id
266-2003
Identifier Type: -
Identifier Source: secondary_id
03-0487-CE
Identifier Type: -
Identifier Source: secondary_id
9848
Identifier Type: -
Identifier Source: org_study_id